David A. Eberhard, MD, PhD
Molecular pathology and genomics of solid tumors. Oncology companion diagnostics. Preclinical and clinical development of novel assays and therapeutics for personalized medicine in oncology. Digital pathology and image analysis of solid tumors.
My work brings previous experience in oncology drug development (at Genentech) and central reference laboratory testing for clinical trials (at LabCorp) to the academic basic and preclinical research activities at UNC. A particular focus of my laboratory’s research is the relationship of molecular heterogeneity in tumor cell populations to therapeutic response and tumor recurrence after treatment. We use molecular, genomic and digital image analysis approaches to identify, characterize and quantify tumor cell subpopulations that may be related to clinical behavior, such as epithelial-mesenchymal transition (EMT) and tumor stem cells.
Kan Z et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 466:869-873, 2010.
Varella-Garcia M et al. EGFR flourescence in-situ hybridization assay: guidelines for application to non-small cell lung cancer. J Clin Pathol 62:970-977, 2009.
Boyd ZS et al. A Tumor Sorting Protocol That Enables Enrichment of Pancreatic Adenocarcinoma Cells and Facilitation of Genetic Analyses. J Mol Diagn 11:290-297, 2009.
Eberhard DA, Giaccone G, Johnson BE. Biomarkers of Response to Epidermal Growth Factor Receptor Inhibitors in Non-Small Cell Lung Cancer: Standardization for Use in the Clinical Setting. J Clin Oncol 26:983-994, 2008.
Peters BA et al. Highly efficient somatic-mutation identification using Escherichia coli mismatch-repair detection. Nature Methods 4:713-715, 2007.
Herbst RS et al. Efficacy and Safety of Single Agent Pertuzumab, a HER Dimerization Inhibitor, in Patients with Non–Small-Cell Lung Cancer. Clin Cancer Res 13:6175-6181, 2007.
Gordon MS et al. Clinical Activity of Pertuzumab (rhuMAb 2C4), a HER Dimerization Inhibitor, in Advanced Ovarian Cancer: Potential Predictive Relationship with Tumor HER2 Activation Status. J Clin Oncol 24:4324-4332, 2006.
Eberhard DA, et al. Mutations in the Epidermal Growth Factor Receptor and in KRAS are predictive and prognostic indicators in non-small cell lung cancers treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 23:5900-5909, 2005.
Yauch RL et al. Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin Cancer Res 11:8686-8698, 2005.
Haas-Kogan DA et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst 97:880-887, 2005.
Herbst RS et al. Phase I/II trial evaluating the anti-VEGF MAb bevacizumab (AvastinTM) in combination with the HER1/EGFR-TK inhibitor, erlotinib (TarcevaTM), for patients with recurrent non-small cell lung cancer. J Clin Oncol 23:2544-2555, 2005.
Eberhard DA. Predictive Diagnostics: KRAS Takes Center Stage. Dako Connection 13:63-68, July 2009 (review). http://www.dako.com/28828_connection_13.pdf
Eberhard DA. The HER Gene Family and Pharmacodiagnostics (Companion Diagnostics): A Tale of Two Targets. Dako Connection 12: 24-30, December 2008 (review). http://www.dako.com/index/knowledgecenter/kc_publications/kc_publications_connection/kc_publications_connection12.htm/28827_2008_conn12_her_gene_family_and_pharmacodiagnostics_eberhard.pdf
Eberhard DA. EGFR Mutations, Other Molecular Alterations Related To Sensitivity to EGFR Inhibitors, and Molecular Testing for EGFR-Targeted Therapies in Non-Small Cell Lung Cancer. In: Haley JD and Gullick WJ, eds. EGFR Signaling Networks in Cancer Therapy, Humana Press, 2008, pp 293-336.
View list of publications from PubMed